Loading…
Nordic distributor of medical devices and equipment, supplying hospitals and clinics across Scandinavia.
Nordic distributor of medical devices and equipment, supplying hospitals and clinics across Scandinavia.
In one line: A Nordic medical-supply distributor like a smaller Owens & Minor.
Moat: none (scale, distribution). Distribution scale across the Nordics helps logistics efficiency, but medical distribution margins are thin and competitive.
Headquarters: Stockholm, Sweden · Founded: 2016 · Employees: 4,580
Size Asker Healthcare (ASKER.ST) is a Sweden Health Care company (Medical Distributors) with a market value of $2.98B, the 60th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 76.10 on 6 Nov 2026.
Performance Over six months the shares fell 5.2%, against +4.7% for the median peer and +8.2% for the Sweden market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 11.7% over the last twelve months (peer median +5.2%); the operating margin is 6.9% (peer median 3.0%).
Valuation It trades at 26.6× forward earnings against a peer median of 15.7× (most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 18.6B | SEK 16.8B | SEK 15.0B | SEK 13.5B | SEK 11.7B |
| Revenue growth | — | +12% | +12% | +15% | — |
| Gross profit | n/a | SEK 6.05B | SEK 5.33B | SEK 4.02B | SEK 3.44B |
| EBITDA | n/a | SEK 2.09B | SEK 1.61B | SEK 1.16B | SEK 1.08B |
| Net income | SEK 761M | SEK 492M | SEK 360M | SEK 203M | SEK 430M |
| Free cash flow | n/a | SEK 738M | SEK 1.07B | SEK 968M | SEK 914M |
| Capital expenditure | n/a | SEK 590M | SEK 348M | SEK 151M | SEK 123M |
| Total debt | n/a | SEK 5.81B | SEK 5.96B | SEK 4.97B | SEK 4.74B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Asker Healthcare ASKER.ST | $2.98B | -5% | +12% | 7% | 26.6× | 1.2% |
| Henry Schein HSIC | $9.51B | +22% | +6% | 6% | 14.8× | 9.8% |
| AddLife ALIF-B.ST | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASKER.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.4% | +3.8% | 5th highest of 21 |
| 6-month return | -5.2% | +4.7% | 5th lowest of 21 |
| Distance from 52-week high | -20.4% | -14.3% | 6th lowest of 21 |
| Revenue growth (TTM) | +11.7% | +5.2% | 2nd highest of 21 |
| Operating margin | 6.9% | 3.0% | 4th highest of 21 |
| Forward P/E | 26.6× | 15.7× | most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 1.2% | -3.7% | 4th most demanding of 17 |
| Growth delivered (Del g) | +12.7% | +4.6% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -11.6 pp | -9.3 pp | 8th least demanding of 17 |
| ROIC minus cost of capital | +10.5 pp | +1.6 pp | 2nd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Asker Healthcare ASKER.ST | Sweden | $2.98B | -5% | +12% | 7% | 26.6× | 1.2% | +12.7% |
| Alfresa 2784.T | Japan | $2.79B | -3% | +5% | 1% | 17.4× | -9.1% | +3.5% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.20B | +5% | +9% | 4% | 15.7× | n/a | n/a |
| Hanmi Science 008930.KS | South Korea | $2.71B | +44% | +6% | 5% | n/a | 24.2% | +9.6% |
| MEDIPAL 7459.T | Japan | $3.67B | +14% | +4% | 1% | 12.6× | -7.4% | +3.5% |
| Amplifon AMP.MI | Italy | $3.72B | +13% | 0% | 9% | 18.1× | 9.5% | +9.8% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 15.0× | -11.9% | +3.2% |
| Jointown Pharmaceutical 600998.SS | China | $3.96B | +1% | +9% | 2% | 11.7× | 0.1% | +7.8% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | n/a | n/a | n/a |
| Galenica GALE.SW | Switzerland | $5.46B | +8% | +6% | 5% | 23.4× | 6.9% | +3.5% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 21.6× | -7.4% | +5.1% |
| DKSH DKSH.SW | Switzerland | $6.10B | +29% | -1% | 3% | 21.5× | -1.4% | +0.6% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 13.8× | -14.7% | +7.6% |
| Sinopharm 1099.HK | Hong Kong | $6.83B | -4% | +3% | 3% | 6.3× | -8.1% | +4.0% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | n/a | -1.3% | +17.9% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 14.2× | -5.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 18.2× | -1.0% | +6.3% |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | n/a | n/a | n/a |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | n/a | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 21.3× | -1.3% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 9.9× | -9.5% | +6.0% |